IBMX
IBMX (3-isobutyl-1-methylxanthine), like other methylated xanthine derivatives, is both a:
- competitive non-selective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNFα and leukotriene synthesis, and reduces inflammation and innate immunity, and
- nonselective adenosine receptor antagonist.
| |||
Names | |||
---|---|---|---|
IUPAC name
1-Methyl-3-(2-methylpropyl)-7H-purine-2,6-dione | |||
Other names
3-Isobutyl-1-methylxanthine | |||
Identifiers | |||
3D model (JSmol) |
|||
ChEBI | |||
ChEMBL | |||
ChemSpider | |||
DrugBank | |||
ECHA InfoCard | 100.044.767 | ||
KEGG | |||
PubChem CID |
|||
UNII | |||
CompTox Dashboard (EPA) |
|||
| |||
SMILES
| |||
Properties | |||
C10H14N4O2 | |||
Molar mass | 222.3 g/mol | ||
Appearance | White solid | ||
Melting point | 199 to 201 °C (390 to 394 °F; 472 to 474 K) | ||
Solubility | Soluble in ethanol, DMSO, and methanol | ||
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references |
As a phosphodiesterase inhibitor, IBMX has IC50 = 2–50 μM and does not inhibit PDE8 or PDE9.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.